bd111
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04560790)
Timeline
Indications
Mechanism of action
- Caspase-9Supplementation
CASP9 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06474442 | Phase 2 | Sep 30, 2024 | Shanghai BDgene Co., Ltd. |
| NCT06474416 | Phase 1 | Sep 4, 2023 | Shanghai BDgene Co., Ltd. |
| NCT04560790 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Fudan University, Shanghai BDgene Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai BDgene Co., Ltd. | For profit | 3 | 3 | 2 | 2020 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1